Adib E, Nassar AH, Abou Alaiwi S, Groha S, Akl EW, Sholl LM, Michael KS, Awad MM, Jnne PA, Gusev A, Kwiatkowski DJ (2022) Variation in targetable genomic alterations in non-small cell lung cancer by genetic ancestry, sex, smoking history, and histology. Genome Med 14:39. https://doi.org/10.1186/s13073-022-01041-x
Article CAS PubMed PubMed Central Google Scholar
Tan AC, Tan DSW (2022) Targeted therapies for lung cancer patients with oncogenic driver molecular alterations. J Clin Oncol 40:611–625. https://doi.org/10.1200/JCO.21.01626
Article CAS PubMed Google Scholar
Santos ES, Rodriguez E (2022) Treatment considerations for patients with advanced squamous cell carcinoma of the lung. Clin Lung Cancer 23:457–466. https://doi.org/10.1016/j.cllc.2022.06.002
Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387:1540–1550. https://doi.org/10.1016/S0140-6736(15)01281-7
Article CAS PubMed Google Scholar
Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M et al (2018) Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378:2078–2092. https://doi.org/10.1056/NEJMoa1801005
Article CAS PubMed Google Scholar
Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gumus M, Mazieres J, Hermes B, Cay Senler F, Csoszi T, Fulop A, Rodriguez-Cid J, Wilson J, Sugawara S, Kato T, Lee KH, Cheng Y, Novello S, Halmos B, Li X et al (2018) Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med 379:2040–2051. https://doi.org/10.1056/NEJMoa1810865
Article CAS PubMed Google Scholar
Carbognin L, Pilotto S, Milella M, Vaccaro V, Brunelli M, Calio A, Cuppone F, Sperduti I, Giannarelli D, Chilosi M, Bronte V, Scarpa A, Bria E, Tortora G (2015) Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PLoS One 10:e0130142. https://doi.org/10.1371/journal.pone.0130142
Article CAS PubMed PubMed Central Google Scholar
Bassanelli M, Sioletic S, Martini M, Giacinti S, Viterbo A, Staddon A, Liberati F, Ceribelli A (2018) Heterogeneity of PD-L1 expression and relationship with biology of NSCLC. Anticancer Res 38:3789–3796. https://doi.org/10.21873/anticanres.12662
Article CAS PubMed Google Scholar
McLaughlin J, Han G, Schalper KA, Carvajal-Hausdorf D, Pelekanou V, Rehman J, Velcheti V, Herbst R, LoRusso P, Rimm DL (2016) Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. JAMA Oncol 2:46–54. https://doi.org/10.1001/jamaoncol.2015.3638
Article PubMed PubMed Central Google Scholar
Nan Z, Guoqing W, Xiaoxu Y, Yin M, Xin H, Xue L, Rong W (2021) The predictive efficacy of tumor mutation burden (TMB) on nonsmall cell lung cancer treated by immune checkpoint inhibitors: a systematic review and meta-analysis. Biomed Res Int 2021:1780860. https://doi.org/10.1155/2021/1780860
Article CAS PubMed PubMed Central Google Scholar
Teng MW, Ngiow SF, Ribas A, Smyth MJ (2015) Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res 75:2139–2145. https://doi.org/10.1158/0008-5472.CAN-15-0255
Article CAS PubMed PubMed Central Google Scholar
Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC, Vonderheide RH, Pittet MJ, Jain RK, Zou W, Howcroft TK, Woodhouse EC, Weinberg RA, Krummel MF (2018) Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med 24:541–550. https://doi.org/10.1038/s41591-018-0014-x
Article CAS PubMed PubMed Central Google Scholar
Saito R, Miki Y, Abe T, Miyauchi E, Abe J, Nanamiya R, Inoue C, Sato I, Sasano H (2020) 11beta hydroxysteroid dehydrogenase 1: a new marker for predicting response to immune-checkpoint blockade therapy in non-small-cell lung carcinoma. Br J Cancer 123:61–71. https://doi.org/10.1038/s41416-020-0837-3
Article CAS PubMed PubMed Central Google Scholar
Ko YS, Pyo JS (2019) Clinicopathological significance and prognostic role of tumor-infiltrating lymphocytes in colorectal cancer. Int J Biol Markers 34:132–138. https://doi.org/10.1177/1724600818817320
Article CAS PubMed Google Scholar
Lanzel EA, Paula Gomez Hernandez M, Bates AM, Treinen CN, Starman EE, Fischer CL, Parashar D, Guthmiller JM, Johnson GK, Abbasi T, Vali S, Brogden KA (2016) Predicting PD-L1 expression on human cancer cells using next-generation sequencing information in computational simulation models. Cancer Immunol Immunother 65:1511–1522. https://doi.org/10.1007/s00262-016-1907-5
Article CAS PubMed PubMed Central Google Scholar
Yoon N, Kim J, Maeng LS, Ahn JH, Park ES (2018) Prominent nucleoli and non-glandular feature are independent predictors of PD-L1 expression in lung adenocarcinoma. Anticancer Res 38:6003–6008. https://doi.org/10.21873/anticanres.12949
Article CAS PubMed Google Scholar
Driver BR, Miller RA, Miller T, Deavers M, Gorman B, Mody D, Ge Y, Barrios R, Bernicker E, Kim M, Cagle PT (2017) Programmed Death Ligand-1 (PD-L1) Expression in either tumor cells or tumor-infiltrating immune cells correlates with solid and high-grade lung adenocarcinomas. Arch Pathol Lab Med 141:1529–1532. https://doi.org/10.5858/arpa.2017-0028-OA
Article CAS PubMed Google Scholar
Nozawa RS, Yamamoto T, Takahashi M, Tachiwana H, Maruyama R, Hirota T, Saitoh N (2020) Nuclear microenvironment in cancer: control through liquid-liquid phase separation. Cancer Sci 111:3155–3163. https://doi.org/10.1111/cas.14551
Article CAS PubMed PubMed Central Google Scholar
Sato H, Niimi A, Yasuhara T, Permata TBM, Hagiwara Y, Isono M, Nuryadi E, Sekine R, Oike T, Kakoti S, Yoshimoto Y, Held KD, Suzuki Y, Kono K, Miyagawa K, Nakano T, Shibata A (2017) DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. Nat Commun 8:1751. https://doi.org/10.1038/s41467-017-01883-9
Article CAS PubMed PubMed Central Google Scholar
Kciuk M, Kolat D, Kaluzinska-Kolat Z, Gawrysiak M, Drozda R, Celik I, Kontek R (2023) PD-1/PD-L1 and DNA damage response in cancer. cells 12:530. https://doi.org/10.3390/cells12040530
Article CAS PubMed PubMed Central Google Scholar
Delahunt B, Cheville JC, Martignoni G, Humphrey PA, Magi-Galluzzi C, McKenney J, Egevad L, Algaba F, Moch H, Grignon DJ, Montironi R (2013) The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol 37:1490–1504. https://doi.org/10.1097/PAS.0b013e318299f0fb
Tsuda H, Akiyama F, Kurosumi M, Sakamoto G, Watanabe T (1998) Establishment of histological criteria for high-risk node-negative breast carcinoma for a multi-institutional randomized clinical trial of adjuvant therapy. Japan National Surgical Adjuvant Study of Breast Cancer (NSAS-BC) Pathology Section. Jpn J Clin Oncol 28:486–491. https://doi.org/10.1093/jjco/28.8.486
Article CAS PubMed Google Scholar
Mori M, Chiba R, Takahashi T (1993) Atypical adenomatous hyperplasia of the lung and its differentiation from adenocarcinoma. Characterization of atypical cells by morphometry and multivariate cluster analysis. Cancer 72:2331–2340. https://doi.org/10.1002/1097-0142(19931015)72:8<2331::aid-cncr2820720808>3.0.co;2-e
Article CAS PubMed Google Scholar
McKenna AM, Pintilie M, Youngson B, Done SJ (2007) Quantification of the morphologic features of fibroepithelial tumors of the breast. Arch Pathol Lab Med 131:1568–1573. https://doi.org/10.5858/2007-131-1568-QOTMFO
Poropatich K, Yang JC, Goyal R, Parini V, Yang XJ (2016) Nuclear size measurement for distinguishing urothelial carcinomas from reactive urothelium on tissue sections. Diagn Pathol 11:57. https://doi.org/10.1186/s13000-016-0501-7
Article PubMed PubMed Central Google Scholar
Kern AJM, Schlomer BJ, Timberlake MD, Peters CA, Hammer MR, Jacobs MA (2017) Simple visual review of pre- to post-operative renal ultrasound images predicts pyeloplasty success equally as well as geometric measurements: a blinded comparison with a gold standard. J Pediatr Urol 13:401 e401–401 e407. https://doi.org/10.1016/j.jpurol.2017.04.005
Schmid M, Vetterli M, Wegener K (2019) Polymer powders for laser-sintering: powder production and performance qualification .AIP Conference Proceedings, 2065, 1, 020008. AIP Publishing LLC
Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P, Hanna W, Jenkins RB, Press MF, Spears PA, Vance GH, Viale G, McShane LM, Dowsett M (2018) Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol 36:2105–2122. https://doi.org/10.1200/JCO.2018.77.8738
Article CAS PubMed Google Scholar
Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP (2018) Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res 28:1747–1756. https://doi.org/10.1101/gr.239244.118
Article CAS PubMed PubMed Central Google Scholar
Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R, Genome Project Data Processing S (2009) The sequence alignment/map format and SAMtools. Bioinformatics 25:2078–2079. https://doi.org/10.1093/bioinformatics/btp352
Article CAS PubMed PubMed Central Google Scholar
Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, Miller CA, Mardis ER, Ding L, Wilson RK (2012) VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res 22:568–576. https://doi.org/10.1101/gr.129684.111
留言 (0)